Cytek Biosciences, Inc. Common Stock (CTKB) Stock
NASDAQ · CTKB
5.58
Fundamentals
Market cap
$734.41M
Price / Earnings ratio
-9.2x
Price / Sales ratio
3.6x
Price / Book ratio
2.3x
Return on assets
-16.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
NeutralCTKBSeptember 17, 2026
Zacks Investment ResearchNeutral
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
CTKB

MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights
NeutralCTKBAugust 6, 2026
MarketBeatNeutral
Cytek Biosciences Q2 Earnings Call Highlights
CTKB

Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
NeutralCTKBAugust 5, 2026
Zacks Investment ResearchNeutral
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
CTKB

Zacks Investment Research
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
NeutralCTKBJuly 29, 2026
Zacks Investment ResearchNeutral
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CTKB
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
242M160M80M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
554M366M183M0
Revenue to Profit
2025$201.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-66.5M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
NeutralCTKBSeptember 17, 2026
Zacks Investment ResearchNeutral
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
CTKB

MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights
NeutralCTKBAugust 6, 2026
MarketBeatNeutral
Cytek Biosciences Q2 Earnings Call Highlights
CTKB

Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
NeutralCTKBAugust 5, 2026
Zacks Investment ResearchNeutral
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
CTKB

Zacks Investment Research
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
NeutralCTKBJuly 29, 2026
Zacks Investment ResearchNeutral
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CTKB

Zacks Investment Research
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
NeutralCTKBJuly 23, 2026
Zacks Investment ResearchNeutral
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
CTKB

Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
NeutralCTKBMay 8, 2026
Zacks Investment ResearchNeutral
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
CTKB

Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
NeutralCTKBFebruary 27, 2026
Zacks Investment ResearchNeutral
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
CTKB

Market Watch
Why these stocks could lose money even if the market gains
NeutralCTKBDecember 1, 2023
Market WatchNeutral
Why these stocks could lose money even if the market gains
CTKB

CNBC Television
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
NeutralCTKBMarch 30, 2023
CNBC TelevisionNeutral
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
CTKB

Seeking Alpha
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
NeutralCTKBJuly 27, 2022
Seeking AlphaNeutral
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
CTKB
About Cytek Biosciences, Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Devices
Employees682
CEODr. Wenbin Jiang Ph.D.
IPO DateJul 22, 2021
HeadquartersFremont, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Wenbin Jiang Ph.D. | President, CEO & Chairman of the Board | 1964 |
| Mr. William D. McCombe | Chief Financial Officer | 1958 |
| Dr. Ming Yan Ph.D. | CTO & Director | 1963 |
| Mr. Paul D. Goodson | Head of Investor Relations | — |
| Mr. Ilan B. Feuchtwang | Chief Legal Officer | — |
| Mr. Patrik Sebastian Jeanmonod | Head of Corporate Development Analytics | 1966 |
Fundamentals
Valuation
Market cap$734.41M
Price-to-sales ratio3.60
Price-to-book value2.31
Price-earnings ratio-9.20
Return on Equity-21.00%
Return on Sales-18.00%
Return on Assets-16.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.62
Income Statement
Average volume1,201,402
EBITDA$-24.55M
1 year high (52w)$6.18
1 year low (52w)$3.28
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.1 | +6.7 | -14.6 | -14.8 | ||||||||
| 2022 | -15.6 | -5.7 | -16.6 | -13.1 | +0.9 | +11.0 | +16.8 | -9.1 | +25.2 | +1.4 | -16.9 | -21.6 |
| 2023 | +19.1 | -16.2 | -3.2 | +29.4 | -33.5 | +4.3 | +8.3 | -14.6 | -28.6 | -22.0 | +64.5 | +27.2 |
| 2024 | -14.9 | -1.4 | -26.7 | -10.3 | -11.6 | +0.9 | +19.6 | -10.5 | +2.8 | -8.2 | +27.8 | -6.2 |
| 2025 | -21.6 | -16.7 | -6.7 | -5.4 | -25.1 | +20.1 | +3.4 | +13.7 | -13.7 | +8.0 | +43.4 | -5.3 |
| 2026 | +1.6 | -13.2 | -1.4 | +1.8 | -9.3 | +4.5 | -7.9 | +10.9 | +22.3 |



